Humana entered a majority-owned BlackRock joint venture managing nearly 150 CenterWell Senior Primary Care clinics, replacing existing joint ventures and expected to reduce liabilities and cost of capital. Humana affirmed FY 2026 adjusted EPS guidance of at least $9.00.
HUM · Humana Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Humana Inc. says final 2027 Medicare Advantage Star Ratings data show it exceeded its Top Quartile goal, expects a one-time 2028 benefit for one-time investments and shareholder returns, and affirms at least $9.00 adjusted EPS for FY 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Jul 29, 2026TL;DR. Humana reported 2Q26 Adjusted EPS of $7.61 and affirmed full-year 2026 Adjusted EPS guidance of at least $9.00 (revising GAAP EPS guidance down to at least $6.52 from at least $8.36), while signaling meaningful margin expansion ahead as 2027 MA bids target a sustainable pre-tax margin of at least 3% by 2028.
- + Reported 2Q26 Adjusted EPS of $7.61 at the high end of expectations (80%-85% of FY)
- + Individual MA membership grew ~23% YTD, tracking to ~25% FY growth target
- + Strategic expansion via $900M Gentiva divestiture funding MaxHealth acquisition and new statewide Illinois Medicaid contract
- + CenterWell Senior Primary Care patients grew 27% YTD with strong retention and NPS gains
- − Revised FY 2026 GAAP EPS guidance down to at least $6.52 from at least $8.36
- − 2027 plan exits will impact approximately 600,000 members
- − Prior period medical claims reserve development was less favorable at $53M in 2Q26 vs $161M in 2Q25
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Healthcare Plans — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HUM
this stock
Humana Inc
|
$50.12B | +60.8% | +10.1% | 39.4 | 3.1% |
|
UNH
Unitedhealth Group Inc
|
$354.57B | +19.9% | +11.8% | 22.6 | 1.6% |
|
CVS
CVS HEALTH Corp
|
$102.31B | +2.5% | +7.8% | 9.3 | 1.3% |
|
ELV
Elevance Health, Inc.
|
$93.81B | +23.2% | +12.5% | 18.4 | 2.4% |
|
CI
Cigna Group
|
$80.70B | +9.5% | +11.2% | 13.5 | 2.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 13, 2026
- This year
- 21
Humana entered a majority-owned BlackRock joint venture managing nearly 150 CenterWell Senior Primary Care clinics, replacing existing joint ventures and expected to reduce liabilities and cost of capital. Humana affirmed FY 2026 adjusted EPS guidance of at least $9.00.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HUM | -1.4% | +6.4% | +35.0% | -0.7% | +60.8% |
| SPY | -4.7% | -5.3% | -0.8% | -3.0% | +7.5% |
| vs SPY | +3.4% | +11.7% | +35.8% | +2.4% | +53.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.